Thrombospondin-1 Serum Levels In Hypertensive Patients With Endothelial Dysfunction After One Year Of Treatment With Perindopril

References

• Krishna SM, Golledge J. The role of thrombospondin-1 in cardiovascular health and pathology. Int J Cardiol. 2013;168(2):692–706. doi:10.1016/j.ijcard.2013.04.13923664438
   PubMed Web of Science ®Google Scholar
• Lawler J. The functions of thrombospondin-1 and-2. CurrOpin Cell Biol. 2000;12(5):634–640.
   PubMed Web of Science ®Google Scholar
• Phelan MW, Forman LW, Perrine SP, Faller DV. Hypoxia increases thrombospondin-1 transcript and protein in cultured endothelial cells. J Lab Clin Med. 1998;132(6):519–529.9851743
   PubMed Web of Science ®Google Scholar
• Isenberg JS, Wink DA, Roberts DD. Thrombospondin-1 antagonizes nitric oxide-stimulated vascular smooth muscle cell responses. Cardiovasc Res. 2006;71(4):785–793. doi:10.1016/j.cardiores.2006.05.02416820142
   PubMed Web of Science ®Google Scholar
• Rogers NM, Yao M, Novelli EM, Thomson AW, Roberts DD, Isenberg JS. Activated CD47 regulates multiple vascular and stress responses: implications for acute kidney injury and its management. Am J Physiol Renal Physiol. 2012;303(8):F1117–25. doi:10.1152/ajprenal.0035922874763
   PubMed Web of Science ®Google Scholar
• Wikner NE, Dixit VM, Frazier WA, Clark RA. Human keratinocytes synthesize and secrete the extracellular matrix protein, thrombospondin. J Invest Dermatol. 1987;88(2):207–211. doi:10.1111/1523-1747.ep125253503543145
   PubMed Web of Science ®Google Scholar
• Dameron KM, Volpert OV, Tainsky MA, Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science. 1994;265(5178):1582–1584. doi:10.1126/science.75215397521539
   PubMed Web of Science ®Google Scholar
• Li SS, Ivanoff A, Bergström SE, et al. T lymphocyte expression of thrombospondin-1 and adhesion to extracellular matrix components. Eur J Immunol. 2002;32(4):1069–1079. doi:10.1002/1521-4141(200204)32:4<1069::AID-IMMU1069>3.0.CO;2-E11920574
   PubMed Web of Science ®Google Scholar
• Lessey-Morillon EC, Roberts DD. Thrombospondin-1: an extracellular message delivered by macrophages that promotes aortic aneurysms. Circ Res. 2015;117(2):113–115. doi:10.1161/CIRCRESAHA.117.30681526139855
   PubMed Web of Science ®Google Scholar
• Smith RE, Reyes NJ, Khandelwal P, et al. Secondary allergic T cell responses are regulated by dendritic cell-derived thrombospondin-1 in the setting of allergic eye disease. J Leukoc Biol. 2016;100(2):371–380. doi:10.1189/jlb.3A0815-357RR26856994
   PubMed Web of Science ®Google Scholar
• Tooney PA, Sakai T, Sakai K, Aeschlimann D, Mosher DF. Restricted localization of thrombospondin-2 protein during mouse embryogenesis: a comparison to thrombospondin-1. Matrix Biol. 1998;17(2):131–143.9694593
   PubMed Web of Science ®Google Scholar
• Chen H, Herndon ME, Lawler J. The cell biology of thrombospondin-1. Matrix Biol. 2000;19(7):597–614.11102749
   PubMed Web of Science ®Google Scholar
• Lopez-Dee Z, Pidcock K, Gutierrez LS. Thrombospondin-1: multiple paths to inflammation. Mediators Inflamm. 2011;296069. doi:10.1155/2011/29606921765615
   PubMed Web of Science ®Google Scholar
• Moura R, Tjwa M, Vandervoort P, Cludts K, Hoylaerts MF. Thrombospondin-1 activates medial smooth muscle cells and triggers neointima formation upon mouse carotid artery ligation. Arterioscler Thromb Vasc Biol. 2007;27(10):2163–2169.17761938
   PubMed Web of Science ®Google Scholar
• Raman P, Krukovets I, Marinic TE, Bornstein P, Stenina OI. Glycosylation mediates up-regulation of a potent antiangiogenic and proatherogenic protein, thrombospondin-1, by glucose in vascular smooth muscle cells. J Biol Chem. 2007;282(8):5704–5714. doi:10.1074/jbc.M61096520017178709
   PubMed Web of Science ®Google Scholar
• Isenberg JS, Ridnour LA, Perruccio EM, Espey MG, Wink DA, Roberts DD. Thrombospondin-1 inhibits endothelial cell responses to nitric oxide in a cGMP-dependent manner. Proc Natl Acad Sci USA. 2005;102(37):13141–13146. doi:10.1073/pnas.050297710216150726
   PubMed Web of Science ®Google Scholar
• Vila V, Martínez-Sales V, Almenar L, Lázaro IS, Villa P, Reganon E. Inflammation, endothelial dysfunction and angiogenesis markers in chronic heart failure patients. Int J Cardiol. 2008;130(2):276–277. doi:10.1016/j.ijcard.2007.07.01017727986
   PubMed Web of Science ®Google Scholar
• Kuebler WM. What mediates the effects of thrombospondin-1 in pulmonary hypertension? New evidence for a dual-pronged role of CD47. Cardiovasc Res. 2017;113(1):3–5. doi:10.1093/cvr/cvw23228069696
   PubMed Web of Science ®Google Scholar
• Roberts DD, Kaur S, Isenberg JS. Regulation of cellular redox signaling by matricellular proteins in vascular biology, immunology, and cancer. Antioxid Redox Signal. 2017;27(12):874–911. doi:10.1089/ars.2017.714028712304
   PubMed Web of Science ®Google Scholar
• Kumar R, Mickael C, Kassa B, et al. TGF-β activation by bone marrow-derived thrombospondin-1 causes Schistosoma- and hypoxia-induced pulmonary hypertension. Nat Commun. 2017;8:15494. doi:10.1038/ncomms1549428555642
   PubMed Web of Science ®Google Scholar
• Thijssen DH, Black MA, Pyke KE, et al. Assessment of flow-mediated dilation in humans: a methodological and physiological guideline. Am J Physiol Heart Circ Physiol. 2011;300(1):H2–H12. doi:10.1152/ajpheart.00471.201020952670
   PubMed Web of Science ®Google Scholar
• Miyamoto M, Kotani K, Ishibashi S, Taniguchi N. The effect of antihypertensive drugs on endothelial function as assessed by flow-mediated vasodilation in hypertensive patients. Int J Vasc Med. 2012;453264. doi:10.1155/2012/45326422489272
   PubMedGoogle Scholar
• Chen JD, Liu M, Chen XH, Yang ZJ. Effect of Angiotensin receptor blockers on flow-mediated vasodilation: a meta-analysis of randomized controlled trials. Cardiology. 2015;131(2):69–79. doi:10.1159/00037525925872009
   PubMed Web of Science ®Google Scholar
• Buda V, Andor M, Petrescu L, et al. Perindopril induces TSP-1 expression in hypertensive patients with endothelial dysfunction in chronic treatment. Int J Mol Sci. 2017;18(2):348. doi:10.3390/ijms18020348
   PubMed Web of Science ®Google Scholar
• Ghimire K, Altmann HM, Straub AC, Isenberg JS. Nitric oxide: what’s new to NO? Am J Physiol Cell Physiol. 2017;312(3):C254–C262. doi:10.1152/ajpcell.00315.201627974299
   PubMed Web of Science ®Google Scholar
• Bauer PM, Bauer EM, Rogers NM, et al. Activated CD47 promotes pulmonary arterial hypertension through targeting caveolin-1. Cardiovasc Res. 2012;93(4):682–693. doi:10.1093/cvr/cvr35622215724
   PubMed Web of Science ®Google Scholar
• Csányi G, Yao M, Rodríguez AI, et al. Thrombospondin-1 regulates blood flow via CD47 receptor-mediated activation of NADPH oxidase 1. Arterioscler Thromb Vasc Biol. 2012;32(12):2966–2973. doi:10.1161/ATVBAHA.112.30003123087362
   PubMed Web of Science ®Google Scholar
• Yao M, Rogers NM, Csányi G, et al. Thrombospondin-1 activation of signal-regulatory protein-α stimulates reactive oxygen species production and promotes renal ischemia reperfusion injury. J Am Soc Nephrol. 2014;25(6):1171–1186. doi:10.1681/ASN.201304043324511121
   PubMed Web of Science ®Google Scholar
• Remková A, Kratochvílová H, Durina J. Impact of the therapy by renin-angiotensin system targeting antihypertensive agents perindopril versus telmisartan on prothrombotic state in essential hypertension. J Hum Hypertens. 2008;22(5):338–345. doi:10.1038/sj.jhh.100232818305548
   PubMed Web of Science ®Google Scholar
• Barclay JL, Keshvari S, Whitehead JP, Inder WJ. Development of an enzyme-linked immunosorbent assay for thrombospondin-1 and comparison of human plasma and serum concentrations. Ann Clin Biochem. 2016;53(Pt 5):606–610. doi:10.1177/000456321662889126748102
   PubMed Web of Science ®Google Scholar
• Buda V, Andor M, Cristescu C, et al. The influence of perindopril on PTX3 plasma levels in hypertensive patients with endothelial dysfunction. Farmacia. 2016;64(3):382–389.
   Web of Science ®Google Scholar
• Buda V, Andor M, Cristescu C, et al. The effect of candesartan on pentraxin-3 plasma levels as marker of endothelial dysfunction in patients with essential arterial hypertension. Ir J Med Sci. 2017;186(3):621–629. doi:10.1007/s11845-017-1580-528220370
   PubMed Web of Science ®Google Scholar
• Buda V, Andor M, Baibata DE, et al. Decreased sEng plasma levels in hypertensive patients with endothelial dysfunction under chronic treatment with Perindopril. Drug Des Devel Ther. 2019;13:1915–1925. doi:10.2147/DDDT.S186378
   PubMed Web of Science ®Google Scholar
• Lamy L, Foussat A, Brown EJ, Bornstein P, Ticchioni M, Bernard A. Interactions between CD47 and thrombospondin reduce inflammation. J Immunol. 2007;178:5930–5939. doi:10.4049/jimmunol.178.9.593017442977
   PubMed Web of Science ®Google Scholar
• Meng Y, Zhang M, Zhao X, et al. Decreased serum thrombospondin-1 and elevation of its autoantibody are associated with multiple exacerbated clinical manifestations in systemic lupus erythematosus. ClinRheumatol. 2018. doi:10.1007/s10067-018-4188-x
   Google Scholar
• Bauer EM, Qin Y, Miller TW, et al. Thrombospondin-1 supports blood pressure by limiting eNOS activation and endothelial-dependent vasorelaxation. Cardiovasc Res. 2010;88(3):471–481. doi:10.1093/cvr/cvq21820610415
   PubMed Web of Science ®Google Scholar
• Wang S, Skorczewski J, Feng X, Mei L, Murphy-Ullrich JE. Glucose up-regulates thrombospondin 1 gene transcription and transforming growth factor-beta activity through antagonism of cGMP-dependent protein kinase repression via upstream stimulatory factor 2. J Biol Chem. 2004;279:34311–34322. doi:10.1074/jbc.M40162920015184388
   PubMed Web of Science ®Google Scholar
• Zhao Y, Pu D, Sun Y, et al. High glucose-induced defective thrombospondin-1 release from astrocytes via TLR9 activation contributes to the synaptic protein loss. Exp Cell Res. 2018;363(2):171–178. doi:10.1016/j.yexcr.2017.12.03029294308
   PubMed Web of Science ®Google Scholar
• Xia Y, Dobaczewski M, Gonzalez-Quesada C, et al. Endogenous thrombospondin 1 protects the pressure-overloaded myocardium by modulating fibroblast phenotype and matrix metabolism. Hypertension. 2011;58:902–911. doi:10.1161/HYPERTENSIONAHA.111.17532321947471
   PubMed Web of Science ®Google Scholar
• Cini C, Yip C, Attard C, et al. Differences in the resting platelet proteome and platelet releasate between healthy children and adults. J Proteomics. 2015;123:78–88. doi:10.1016/j.jprot.2015.04.00325868662
   PubMed Web of Science ®Google Scholar
• Kareva I, Abou-Slaybi A, Dodd O, Dashevsky O, Klement GL. Normal wound healing and tumor angiogenesis as a game of competitive inhibition. PLoS One. 2016;11(12):e0166655. doi:10.1371/journal.pone.016665527935954
   PubMed Web of Science ®Google Scholar
• Ma L, Perini R, McKnight W, et al. Proteinase-activated receptors 1 and 4 counter-regulate endostatin and VEGF release from human platelets. Proc Natl Acad Sci U S A. 2005;102(1):216–220. doi:10.1073/pnas.040668210215615851
   PubMed Web of Science ®Google Scholar
• Burger P, Hilarius-Stokman P, de Korte D, van Den Berg TK, van Bruggen R. CD47 functions as a molecular switch for erythrocyte phagocytosis. Blood J. 2012;119:5512–5521. doi:10.1182/blood-2011-10-386805
   PubMed Web of Science ®Google Scholar
• Spencer CG, Felmeden DC, Blann AD, Lip GY. Effects of “newer” and “older” antihypertensive drugs on hemorrheological, platelet, and endothelial factors. A substudy of the Anglo-Scandinavian Cardiac Outcomes Trial. Am J Hypertens. 2007;20(6):699–704. doi:10.1016/j.amjhyper.2007.01.00417531931
   PubMed Web of Science ®Google Scholar